/
INTS
$4.04-$0.06 (-1.59%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$11.1M
3M shares
52-week range
$3.51 – $43.50
1% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
11.75%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-144.97
Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
www.intensitytherapeutics.com- Employees
- 7
- IPO / List date
- Jun 30, 2023
- HQ
- SHELTON, CT
Held by traders on TradeandTell
No one on the platform currently holds INTS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in INTS as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-02-19 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded INTS yet.
